Streetbeat News

ROIV

Roivant Sciences Ltd.

https://roivant.com

Industry

Biotechnology

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Roivant Sciences (NASDAQ:ROIV) with a maintained price target of $18.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 10:34 am

Goldman Sachs analyst Corinne Jenkins has maintained a Buy rating on Roivant Sciences (NASDAQ:ROIV) and increased the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:18 pm

HC Wainwright & Co. analyst Douglas Tsao maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $17 to $18.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:05 am

Deutsche Bank analyst Neena Bitritto-Garg maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $14 to $15.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 9:14 am

Roivant Sciences (NASDAQ:ROIV) and Priovant Therapeutics announced positive results from the Phase 2 NEPTUNE study of brepocitinib in non-anterior non-infectious uveitis (NIU), showing significant treatment benefits. Additionally, Roivant's board authorized a share repurchase program for up to $1.5 billion, including buying back shares from Sumitomo Pharma, which will reduce outstanding shares by about 9%. ROIV shares rose 5.37% to $10.99.

Portfolio Pulse from Vandana Singh

April 02, 2024 | 4:31 pm

Roivant Sciences shares surged following the announcement of positive results from its NEPTUNE Phase 2 study of brepocitinib. Additionally, the company's board approved a share repurchase program of up to $1.5 billion, which includes buying back all 71.3 million shares owned by Sumitomo Pharma.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:28 am

Roivant Sciences announced a board authorization for a share repurchase program up to $1.5B, including buying back the entire stake of Sumitomo Pharma for $648M, reducing shares outstanding by 9%.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:12 am

Roivant Sciences announced positive results from its NEPTUNE study for Brepocitinib in treating non-infectious uveitis. This development could significantly impact Roivant's market position and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 11:10 am

Today's session highlighted significant whale activity in the Health Care sector, focusing on options trading. Notable bullish sentiment was observed in trades for ROIV, EXAS, ESTA, MDT, THC, and ISRG, with bearish sentiment for PFE, BSX, and NVO. FULC displayed neutral sentiment. The activity involved both call and put options across various expiration dates and strike prices, indicating diverse market expectations and strategies among large investors.

Portfolio Pulse from Benzinga Insights

March 29, 2024 | 5:35 pm

Roivant Sciences' stock is trading higher following the announcement that it will be included in the S&P MidCap 400 index.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:16 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.